Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Devalingam Mahalingam

Status

Conditions: Hepatocellular Carcinoma

Treatments: Drug: G-202

Study type: Expanded Access

Funder types: Other; Industry

Identifiers

NCT02082691

CTRC 13-0040

HSC20130391T [UTHSCSA IRB]

Details and patient eligibility

About

Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of hepatocellular carcinoma
• Participation in prior research study where G-202 was administered
• Tolerance of G-202 treatment
• Demonstration of stable disease

Exclusion criteria

• Disease progression
• Occurrence of unacceptable toxicity